These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30661834)

  • 1. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.
    Scholz S; Koerber F; Meszaros K; Fassbender RM; Ultsch B; Welte RR; Greiner W
    Vaccine; 2019 Mar; 37(12):1692-1701. PubMed ID: 30661834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain.
    Ivanova-Markova Y; González-Domínguez A; Hidalgo A; Sánchez R; García-Agua N; García-Ruiz AJ; Amanda Vallejo-Aparicio L; García A; Rodriguez R; de Gomensoro E; Gonzalez-Inchausti MDC; Shen J; Begum N; Tafalla M
    Vaccine; 2021 Dec; 39(52):7646-7654. PubMed ID: 34794819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands-a Holistic Approach.
    Zeevat F; Simons JJM; Westra TA; Wilschut JC; van Sorge NM; Boersma C; Postma MJ
    Infect Dis Ther; 2024 Mar; 13(3):481-499. PubMed ID: 38366286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
    de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
    Pharmacoecon Open; 2024 Jul; 8(4):539-557. PubMed ID: 38780884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.
    Beck E; Klint J; Neine M; Garcia S; Meszaros K
    Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 9. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
    Findlow J; Nuttens C; Kriz P
    Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and economic burden of meningococcal disease in Germany: A systematic review.
    Gruhn S; Witte J; Greiner W; Damm O; Dietzsch M; Kramer R; Knuf M
    Vaccine; 2022 Mar; 40(13):1932-1947. PubMed ID: 35227520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children.
    Wang B; Haji Ali Afzali H; Marshall H
    Vaccine; 2014 Aug; 32(37):4791-8. PubMed ID: 24998605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive meningococcal disease in the Veneto region of Italy: a capture-recapture analysis for assessing the effectiveness of an integrated surveillance system.
    Baldovin T; Lazzari R; Cocchio S; Furlan P; Bertoncello C; Saia M; Russo F; Baldo V
    BMJ Open; 2017 May; 7(4):e012478. PubMed ID: 28465304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database.
    Huang L; Heuer OD; Janßen S; Häckl D; Schmedt N
    PLoS One; 2020; 15(1):e0228020. PubMed ID: 31990941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.
    La EM; Talbird SE; Kanadanian KV; Huang L; Fain J; Srivastava A
    Hum Vaccin Immunother; 2019; 15(4):978-986. PubMed ID: 30526279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular typing of group B Neisseria meningitidis'subcapsular antigens directly on biological samples demonstrates epidemiological congruence between culture-positive and -negative cases: A surveillance study of invasive disease over a 13-year period.
    Lodi L; Moriondo M; Nieddu F; Ricci S; Guiducci S; Lippi F; Canessa C; Calistri E; Citera F; Giovannini M; Indolfi G; Resti M; Azzari C
    J Infect; 2021 Apr; 82(4):28-36. PubMed ID: 33610687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease.
    Marten O; Koerber F; Bloom D; Bullinger M; Buysse C; Christensen H; De Wals P; Dohna-Schwake C; Henneke P; Kirchner M; Knuf M; Lawrenz B; Monteiro AL; Sevilla JP; Van de Velde N; Welte R; Wright C; Greiner W
    Health Qual Life Outcomes; 2019 May; 17(1):87. PubMed ID: 31118091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N
    Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Australian Meningococcal Surveillance Programme annual report, 2019.
    Lahra MM; Hogan TR;
    Commun Dis Intell (2018); 2020 Aug; 44():. PubMed ID: 32829701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.
    Hellenbrand W; Koch J; Harder T; Bogdan C; Heininger U; Tenenbaum T; Terhardt M; Vogel U; Wichmann O; von Kries R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1314-43. PubMed ID: 26487381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.